Figure 1. BRAF inhibitor-induced changes in cell viability.

BRAF-mutant melanoma (A) and colorectal cancer (B) cell lines were treated with respective inhibitors at 1 μM for 48 hours prior to measuring luminescence. Changes in viability were measured using RealTime-Glo™ MT Cell Viability Assay and reported relative to vehicle-treated control. Mean values with standard deviations plotted from 5 replicates. Significance levels legend: Not significant (NS) P > 0.05; ^* P ≤ 0.05; ^** P ≤ 0.01; ^*** P ≤ 0.001; ^**** P ≤ 0.0001. N.B. Statistics for all drugs vs control not shown for ease of display and interpretation, all 3 compounds highly significant (P < 0.0001). Drug dose response curves. Sensitivity to respective BRAF inhibitors was evaluated in melanoma (C) and colorectal (D) cell lines. Cells were treated with 10,000-fold dilution series (0.001 μM to 10 μM) of respective BRAF inhibitors for 48 hours. Cell viability was assessed using RealTime-Glo™ MT Cell Viability Assay and reported relative to vehicle-treated control. The x-axis represents the log transformed inhibitor dose concentration. Mean values with standard deviation plotted from five replicates. (E) Derived IC₅₀ values of BRAF inhibitors in melanoma and CRC cell lines (half-filled and filled symbols, respectively).